1471-244X-5-44 1471-244X Correction <p>Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]</p> Carey D Paul pcarey@sun.ac.za Vythilingum Bavanisha bv@sun.ac.za Seedat Soraya sseedat@sun.ac.za Muller E Jacqueline jemuller@sun.ac.za van Ameringen Michael vanamer@mcmaster.ca Stein J Dan djs2@sun.ac.za

MRC Research Unit on Anxiety Disorders, University of Stellenbosch, Cape Town, South Africa

Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, Ontario, Canada

 BMC Psychiatry 1471-244X 2005 5 1 44 http://www.biomedcentral.com/1471-244X/5/44 10.1186/1471-244X-5-44 25 11 2005 30 11 2005 30 11 2005 2005 Carey et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The comment in the introduction of our article 1 suggesting that "quetiapine is the only available antipsychotic with significant 5-HT1D effects," is misleading. The affinity of quetiapine for this receptor is low and probably insignificant when compared with some other second generation antipsychotics 2.

 <p>Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]</p> Carey PD Vythilingum B Seedat S Muller JE van AM Stein DJ BMC Psychiatry 2005 5 5 547907 15667657 10.1186/1471-244X-5-5 <p>Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds</p> Richelson E Souder T Life Sci 2000 68 29 39 10.1016/S0024-3205(00)00911-5 11132243

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-244X/5/44/prepub